Our research has produced innovations around IUD contraception. These findings have been integrated in IUD products that are available on the market today. We are constantly working on improving our current products and developing new innovations for IUD contraception.
GyneFix® is a very small copper containing intrauterine device (IUD). It is suitable for insertion in all women regardless the seize of their uterine cavity. The device is frameless, lacking a crossarm, is flexible and, when inserted properly, the majority of women will keep the IUD for the full lifespan of the IUD of 5 years. A new frameless device that last for more than 10 years will be available in 2017, which could be used from young age until the woman is ready to have her first child which is around the age of 30 in Europe and 29 in the North America on average. The size of an IUD is closely related to the side effects it causes, so that smaller devices are better tolerated with less effect on the amount of blood loss.
A new surgical focused approach was devised for suspending the frameless copper IUD for intracesarean insertion which takes advantage of the full visualization and access to the uterus that is achieved during cesarean delivery. The technique consists of the precise placement and fixation of a tiny anchoring knot in the fundus of the uterus immediately after delivery and expulsion of the placenta. The technique is simple, safe and effective to prevent IUD expulsion. The entire procedure can be performed in under 4 minutes with no discomfort to the patient and minimal surgical risk.
ReLARC (Reversible Long-Acting Reproductive Control is a new hysteroscopic technique for the insertion of long-term contraceptive devices. The procedure is conducted under direct visualization.
The method is simple, safe and rapid, and is suitable for application in the operating room or the office. The method is a reversible alternative to more complex insertion techniques for hysteroscopic irreversible intratubal contraception. It is the first hysteroscopically inserted system suitable for long-term intrauterine contraception up to 10 years.
Femilis Cu-T 300
It is a T-shaped copper-releasing IUD (left) derived from the T-shaped Femilis® LNG-IUS and the frameless copper IUD, GyneFix®. The copper cylinders are open to the endometrial environment, therefore releasing a high amount of copper ions to prevent fertilization. The IUD is significantly smaller that the T-shaped® IUD, with shorter retention arm as well as stem. The device is therefore more suitable for the smaller uterine cavities of nulliparous women. Insertion is easily and safely accomplished by pushing the device in the uterine cavity (push-in technique). Provider training is therefore limited. The inserter tube is only 3 mm in diameter.
It is an anchored levonorgestrel-releasing Intrauterine System (IUS). It consists of a 3.5-cm long and 1.6 mm wide fibrous delivery system, releasing approximately 20 μg of LNG per day. The system is effective for five years. The indications for Fibroplant are: Treatment of idiopathic menorrhagia; contraception; endometrial suppression in women using estrogen for postmenopausal treatment. FibroPlant® is highly effective for these indications. As the fiber fits in cavities of every size and shape, it will be well tolerated and therefore it is also highly suitable for young women suffering from severe dysmenorrhea, often associated with heavy menstrual bleeding.
Femilis consists of a 3 cm long and a 2.4 mm wide drug delivery compartment. The vertical drug delivery rod contains 60 mg of levonorgestrel (LNG), and is covered by a rate-controlling membrane. The drug delivery compartment releases approximately 20 μg of LNG in vitro daily. The transverse retention arm has a length of either 28 mm or 24 mm to accommodate different widths of uterine cavities. Femilis® LNG-IUS is inserted using the simple and safe push-in technique, requiring minimal training. The insertion of Femilis® is apparently simpler than that required for other conventional T-shaped devices, since its arms are folded downward during the insertion process. Over 10 years of experience has been accumulated with the T-shaped LNG-IUS.
Femilis Slim LNG-IUS
The small Femilis® Slim with average release of 14 μg per day of LNG over a 5-years has shown to be highly suitable for endometrial suppression in postmenopausal women in combination with parenteral estrogen substitution therapy. The low systemic absorption of LNG could be desirable, thus allowing for maximization of the beneficial effects of ET on organ tissues (e.g. cardiovascular tissues and breast). Use of the LNG-IUS is associated with high patient satisfaction. The risk of breast cancer may not be increased due to the very low systemic levels of the progestogen, in contrast with systemic progestogen administration.
In his clinic in Ghent, Dr. Wildemeersch organizes training sessions for doctors from inside and outside Belgium, interested in learning the anchoring technique of frameless intrauterine devices.
The clinic is specialized in providing precision intrauterine contraception to fulfill women's needs.